Forte Biosciences (NASDAQ:FBRX) Sees Unusually-High Trading Volume – Should You Buy?

Shares of Forte Biosciences, Inc. (NASDAQ:FBRX) saw unusually-high trading volume on Friday . 296,858 shares were traded during mid-day trading, a decline of 9% from the previous session’s volume of 324,963 shares.The stock last traded at $43.3090 and had previously closed at $36.70.

Key Stories Impacting Forte Biosciences

Here are the key news stories impacting Forte Biosciences this week:

• Positive Sentiment: FB102 delivered statistically significant improvement in vitiligo in a Phase 1b study, supporting the drug’s clinical potential and fueling investor optimism. FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
• Positive Sentiment: Analysts and commentary suggest FB102 may be evolving into a broader platform story, with evidence of activity in both vitiligo and celiac disease, which could expand the market opportunity beyond a single indication. Forte Biosciences: FB102 Is Becoming A Platform Story, Not A Single-Indication Bet
• Positive Sentiment: The company’s pro forma cash balance of about $220 million gives it a long runway to fund upcoming Phase II/III development, reducing near-term financing risk. Forte Biosciences: FB102 Is Becoming A Platform Story, Not A Single-Indication Bet
• Neutral Sentiment: Forte Biosciences also discussed the Phase 1b vitiligo results and FB102’s mechanism of action in a transcript-style update, reinforcing the same positive trial narrative. Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action Transcript
• Neutral Sentiment: Trading was briefly halted for an LULD pause, reflecting unusual volatility as the stock reacted to the clinical update. Trading Halt Notice

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Forte Biosciences from a “strong sell” rating to a “sell” rating in a report on Monday, May 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Forte Biosciences in a report on Wednesday. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $67.00.

Forte Biosciences Stock Up 17.7%

The firm has a 50 day moving average of $21.03 and a 200 day moving average of $26.12. The firm has a market cap of $599.80 million, a price-to-earnings ratio of -9.47 and a beta of 2.85.

Forte Biosciences (NASDAQ:FBRX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.08). Equities analysts expect that Forte Biosciences, Inc. will post -4.27 EPS for the current year.

Institutional Investors Weigh In On Forte Biosciences

A number of large investors have recently bought and sold shares of the stock. Global Retirement Partners LLC bought a new stake in Forte Biosciences in the fourth quarter valued at $27,000. Bank of America Corp DE grew its stake in shares of Forte Biosciences by 5,641.8% in the 3rd quarter. Bank of America Corp DE now owns 3,158 shares of the company’s stock valued at $47,000 after buying an additional 3,103 shares during the period. Dimensional Fund Advisors LP acquired a new stake in shares of Forte Biosciences in the 3rd quarter valued at about $161,000. Jane Street Group LLC acquired a new stake in shares of Forte Biosciences in the 4th quarter valued at about $228,000. Finally, Citadel Advisors LLC bought a new stake in Forte Biosciences in the 3rd quarter valued at about $234,000. 77.63% of the stock is currently owned by institutional investors and hedge funds.

About Forte Biosciences

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.